Cancer Cell Int. 2014 May 19;14:42. doi: 10.1186/1475-2867-14-42. eCollection 2014.

Glutamate involvement in calcium-dependent migration of astrocytoma cells.

Cancer cell international

Abdelkader Hamadi, Grégory Giannone, Kenneth Takeda, Philippe Rondé

PMID: 24860258 PMCID: PMC4032497 DOI: 10.1186/1475-2867-14-42

Abstract

BACKGROUND: Astrocytoma are known to have altered glutamate machinery that results in the release of large amounts of glutamate into the extracellular space but the precise role of glutamate in favoring cancer processes has not yet been fully established. Several studies suggested that glutamate might provoke active killing of neurons thereby producing space for cancer cells to proliferate and migrate. Previously, we observed that calcium promotes disassembly of integrin-containing focal adhesions in astrocytoma, thus providing a link between calcium signaling and cell migration. The aim of this study was to determine how calcium signaling and glutamate transmission cooperate to promote enhanced astrocytoma migration.

METHODS: The wound-healing model was used to assay migration of human U87MG astrocytoma cells and allowed to monitor calcium signaling during the migration process. The effect of glutamate on calcium signaling was evaluated together with the amount of glutamate released by astrocytoma during cell migration.

RESULTS: We observed that glutamate stimulates motility in serum-starved cells, whereas in the presence of serum, inhibitors of glutamate receptors reduce migration. Migration speed was also reduced in presence of an intracellular calcium chelator. During migration, cells displayed spontaneous Ca(2+) transients. L-THA, an inhibitor of glutamate re-uptake increased the frequency of Ca(2+) oscillations in oscillating cells and induced Ca(2+) oscillations in quiescent cells. The frequency of migration-associated Ca(2+) oscillations was reduced by prior incubation with glutamate receptor antagonists or with an anti-β1 integrin antibody. Application of glutamate induced increases in internal free Ca(2+) concentration ([Ca(2+)]i). Finally we found that compounds known to increase [Ca(2+)]i in astrocytomas such as thapsigagin, ionomycin or the metabotropic glutamate receptor agonist t-ACPD, are able to induce glutamate release.

CONCLUSION: Our data demonstrate that glutamate increases migration speed in astrocytoma cells via enhancement of migration-associated Ca(2+) oscillations that in turn induce glutamate secretion via an autocrine mechanism. Thus, glutamate receptors are further validated as potential targets for astrocytoma cancer therapy.

Keywords: Calcium spikes; Glutamate release; Migration; U-87MG cell

References

1. Biochim Biophys Acta. 2011 May;1813(5):984-91 - PubMed
2. Biophys J. 1995 Apr;68(4):1207-17 - PubMed
3. J Cell Biol. 1999 Nov 1;147(3):611-8 - PubMed
4. Biochim Biophys Acta. 2000 Dec 20;1498(2-3):91-8 - PubMed
5. Cancer Res. 1999 Sep 1;59(17):4383-91 - PubMed
6. Cancer Res. 2007 Oct 1;67(19):9463-71 - PubMed
7. Glia. 1998 Mar;22(3):237-48 - PubMed
8. J Neurosci. 1999 Dec 15;19(24):10767-77 - PubMed
9. Mol Biol Cell. 2011 Apr;22(7):964-75 - PubMed
10. J Physiol. 2009 May 15;587(Pt 10):2197-209 - PubMed
11. J Neurosci. 1998 Sep 1;18(17):6822-9 - PubMed
12. Nat Cell Biol. 2004 Oct;6(10):977-83 - PubMed
13. J Neurosci. 2000 Jan 15;20(2):666-73 - PubMed
14. J Neurochem. 2001 Jul;78(2):365-73 - PubMed
15. J Biol Chem. 1995 Apr 28;270(17):9917-25 - PubMed
16. J Neurochem. 1997 Oct;69(4):1467-75 - PubMed
17. Glia. 1999 Mar;26(1):1-11 - PubMed
18. Science. 1992 Aug 7;257(5071):806-9 - PubMed
19. Neuron. 1996 Aug;17(2):275-85 - PubMed
20. Neuron. 1995 Jun;14(6):1233-46 - PubMed
21. Biochim Biophys Acta. 2000 Dec 20;1498(2-3):273-80 - PubMed
22. Eur J Pharmacol. 1995 Apr 28;289(2):395-7 - PubMed
23. Nature. 1995 Oct 12;377(6549):539-44 - PubMed
24. Histochem Cell Biol. 2009 Oct;132(4):435-45 - PubMed
25. J Neurosci. 1999 Jun 1;19(11):4449-61 - PubMed
26. J Leukoc Biol. 1997 Feb;61(2):188-200 - PubMed
27. J Neurosci. 1990 May;10(5):1583-91 - PubMed
28. J Neurosci. 2005 Aug 3;25(31):7101-10 - PubMed
29. Nature. 1995 Sep 7;377(6544):75-9 - PubMed
30. Science. 1993 Apr 2;260(5104):95-7 - PubMed
31. Blood. 1996 Mar 1;87(5):2038-48 - PubMed
32. EMBO J. 1997 Sep 15;16(18):5592-9 - PubMed
33. Nat Cell Biol. 2000 May;2(5):249-56 - PubMed
34. J Cell Biol. 1992 Jan;116(1):219-26 - PubMed
35. J Physiol. 2003 Dec 1;553(Pt 2):407-14 - PubMed
36. Nature. 1990 Nov 29;348(6300):443-6 - PubMed
37. J Biol Chem. 2002 Jul 19;277(29):26364-71 - PubMed
38. Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H315-23 - PubMed
39. Cancer Biol Ther. 2007 Dec;6(12):1908-15 - PubMed
40. PLoS One. 2010 Nov 30;5(11):e15090 - PubMed
41. Biochem Pharmacol. 1989 Oct 1;38(19):3207-12 - PubMed
42. Neuro Oncol. 2009 Jun;11(3):260-73 - PubMed
43. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7 - PubMed
44. J Cell Sci. 2000 Feb;113 ( Pt 4):653-62 - PubMed
45. J Cell Sci. 2002 Sep 1;115(Pt 17):3415-25 - PubMed
46. Nat Cell Biol. 2004 Feb;6(2):154-61 - PubMed
47. J Biol Chem. 1996 Nov 15;271(46):28942-6 - PubMed
48. Neuropharmacology. 1993 Sep;32(9):833-7 - PubMed
49. Neurochem Res. 1997 Sep;22(9):1127-33 - PubMed
50. J Biol Chem. 2004 Jul 2;279(27):28715-23 - PubMed
51. J Biol Chem. 2002 Nov 1;277(44):41480-8 - PubMed
52. J Neurosci. 2000 Mar 1;20(5):1800-8 - PubMed
53. Mol Cell Endocrinol. 1998 May 25;140(1-2):89-94 - PubMed
54. Biochim Biophys Acta. 2004 Jul 5;1692(2-3):77-102 - PubMed
55. J Cell Biol. 1998 Oct 5;143(1):241-52 - PubMed
56. Oncogene. 2000 Nov 20;19(49):5606-13 - PubMed
57. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9021-6 - PubMed
58. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8 - PubMed
59. Physiol Rev. 2013 Oct;93(4):1621-57 - PubMed

Publication Types

• Journal Article